Egon Pfarr

Binger Str. 173
Ingelheim Am Rhein, RP 55216, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Safety of empagliflozin treatment in four clinical studies: a plain language summary.

Safety of empagliflozin treatment in four clinical studies: a plain language summary.

Journal: Current medical research and opinion

Published: August 22, 2025

Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial.

Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial.

Journal: Clinical therapeutics

Published: May 15, 2025

Safety and efficacy of empagliflozin in heart failure among patients with a history of valvular heart disease: Insights from EMPEROR-Pooled.

Safety and efficacy of empagliflozin in heart failure among patients with a history of valvular heart disease: Insights from EMPEROR-Pooled.

Journal: JTCVS open

Published: December 20, 2024

Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled.

Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled.

Journal: JACC. Advances

Published: November 13, 2024

Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.

Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.

Journal: Advances in therapy

Published: March 04, 2024

Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial.

Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial.

Journal: European journal of heart failure

Published: October 20, 2023

Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.

Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.

Journal: Circulation

Published: November 07, 2022

Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial.

Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial.

Journal: European journal of heart failure

Published: November 04, 2022

Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.

Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.

Journal: Diabetes, obesity & metabolism

Published: September 23, 2022

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.

Journal: European journal of heart failure

Published: August 09, 2022

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.

Journal: Clinical kidney journal

Published: September 03, 2021

Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.

Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.

Journal: Circulation

Published: August 16, 2021

Showing 1-12 of 38

Last Updated: 09/26/2026